Introduction: To assess a potential relationship between sex and outcome in
| INTRODUCTION
Implantable cardioverter-defibrillator (ICD) therapy is associated with a significant reduction in overall mortality in patients at high risk for ventricular arrhythmias. [1] [2] [3] [4] [5] Previous data indicated that the outcome of ICD therapy is different between female and male patients. [6] [7] [8] However, it is still controversial to what extent the outcome of ICD therapy is influenced by sex and if this should impact on programming strategies. Recent studies from European registries reported that females have lower mortality rates compared to men. [6] [7] [8] In contrast to these results, data from an Israeli registry 9 and a North-American registry 10 could not identify a difference in overall survival (OS). The
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present large-scale study aims to assess sex-related differences in the outcome of ICD therapy in an unselected real-world population and its possible impact on treatment strategies. 
| METHODS

| Design and study population
This
| Data source
The data source for the underlying study was the database of the Arrhythmia Outpatient Department of the Medical University of Vienna.
It is used for daily routine and provided all relevant data that was required for the underlying study, including accurate information on occurrence and classification of ICD therapy and patient's mortality. 
| Outcome parameters
The primary endpoint was time to antitachycardia pacing (ATP) or shock therapy. All-cause mortality was the secondary endpoint. In case of death, physicians and family members, as well as witnesses, were interviewed for detailed circumstances. and device type (VVI, DDD, and CRT-D). Variables with a P < .10
| Statistical analysis
were included in the multivariate analysis.
| RESULTS
The study enrolled a total of 1471 ICD recipients: 265 (18%)
were female and 1206 (82%) were male patients. Baseline clinical characteristics are presented in Table 1 . Follow-up time did not differ between the two groups. Female patients suffered less often from ischemic heart disease, but more often from hypertrophic cardiomyopathy, channelopathies and "other" rare conditions such as postmyocarditis, congenital heart disease, and severe valvular heart disease. Women were less often treated with antiarrhythmic drugs class 3 and had a better left ventricular function. Females were more often implanted with a dual chamber ICD (DDD) and had less frequent hypertension and hyperlipidemia (details see Table 1 ).
| Overall survival
Kaplan-Meier analysis showed no significant difference in OS between female and male patients (P = .132; Figure 1 ). After 5 and 10 years of follow-up, the probability for OS was 77.0% and 67.7% in female patients and 74.6% and 55.4% in male patients, respectively.
Univariate and multivariate Cox regression analysis was performed to determine predictors for overall mortality and to account for potential confounding factors. In the multivariate analysis, age 
| 1621
Kaplan-Meier analysis revealed no significant difference between sex in OS in patients stratified according to the prevention strategy:
primary prevention (P = .403) and secondary prevention (P = .137).
| First inappropriate therapy
Kaplan-Meier analysis was performed to analyze the time until the first occurrence of inappropriate ATP and shock therapy. There was no significant difference in first inappropriate ATP (P = .468) and first inappropriate shock therapy (P = .812; Figure 2 ) between female and male patients. After 5 and 10 years of follow-up, the probability for 
| Incidence of inappropriate therapy
A total of 1783 events of inappropriate ATP and 968 events of inappropriate shock therapy occurred in the overall study population.
Rate per patient year for inappropriate ATP and shock therapy ranged between 0.11 and 0.36 and did not differ significantly (Table 2) . Negative binomial regression analysis did not reveal a significant difference between female and male patients in inappropriate ATP (RR = 1.22; 95% CI, 0.42-3.59; P = .715) and in inappropriate shock therapy (RR = 0.64; 95% CI, 0.36-1.13; P = .121).
| Incidence of appropriate therapy
A total of 12 965 events of appropriate ATP and 2173 events of appropriate shock therapy occurred in the overall study population. Rate per patient year of appropriate ATP was 0.98 in female patients, compared with 2.42 in male patients (Table 2) . Negative binomial regression analysis revealed a lower incidence of appropriate ATP in female patients compared with male patients (RR = 0.37; 95% CI, 0.14- 
| DISCUSSION
The main findings of the underlying study are that (a) female and male patients equally benefit from ICD therapy, (b) OS and inappropriate therapy are independent of sex, and (c) women receive less appropriate ATP therapies. 10 did not identify a significant difference in overall mortality between sex in patients with primary and secondary ICD indication.
This result was confirmed by an Israeli registry that also included primary and secondary preventive ICD recipients. 9 Patients were followed for 1 year in the North-American registry 10 and for a median of 323 days in the Israeli registry. 9 Thus, the present study provides new and valuable long-term data in this context.
Inappropriate ATP and shock therapy represent an anticipated risk in ICD therapy. Previous research showed that inappropriate therapy is associated with worse clinical outcome and increased overall mortality. 12, 13 Optimized ICD programming strategies and discrimination algorithms are crucial to reduce inappropriate therapy burden in primary and secondary prevention. [14] [15] [16] [17] Sex-specific differences in the occurrence of inappropriate therapy were reported F I G U R E 1 Kaplan-Meier curves analyzing overall survival stratified for sex LVEF is still the gold standard for selection of patients at risk for life-threatening ventricular arrhythmias. ICD recipients with mild to moderate reduced LVEF might be particularly affected, because even those patients are at risk for arrhythmias during long-term follow-up. 19, 20 In the underlying study, we did not observe sex-related differences in regards to LVEF.
In this unselected study cohort, females represent the minority of ICD recipients with only 18% of all patients implanted between 2000
and 2015. This is in line with data from registries that report a proportion of female patients ranging between 15.1% and 21.2%. [6] [7] [8] [9] Likewise, in major ICD landmark studies, women account for the minority of the study population. answer on the degree of ICD benefit in both sexes.
| CONCLUSION
The underlying study demonstrates that female and male patients equally benefit from ICD therapy. OS and rates of appropriate shock therapy are similar in both groups, whereas rates of appropriate ATP are lower in female patients. Women and men have the same risk for inappropriate therapy.
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